Last reviewed · How we verify
Butyphthalide combined with rtPA
At a glance
| Generic name | Butyphthalide combined with rtPA |
|---|---|
| Sponsor | Hui-Sheng Chen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Butyphthalide combined with rtPA CI brief — competitive landscape report
- Butyphthalide combined with rtPA updates RSS · CI watch RSS
- Hui-Sheng Chen portfolio CI